Health TrialsbyHealthPanel

Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19

ConditionsLung FunctionExercise CapacityQuality of LifeCovid19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese University of Hong Kong

About this trial

(a) Objectives

1. To assess the full lung function, exercise capacity, quality of life in patients with COVID-19 over 2 years. 2. To assess the longevity of the serology response to SARS-CoV2. 3. To investigate the association of the neutralization titer in plasma from different vaccinated cohorts to its protection of infection using in vivo model 4. To investigate the SARS-CoV-2 specific cellular and humoral immunities as well as their determinant factors from community subjects who have received different types of COVID-19 vaccines. 5. To assess the third booster dose for subjects who have poor antibody response despite having received two doses of CoronaVac (Sinovac)

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Adult patients (about 80) who have been discharged following treatment for COVID-19 will be followed up at the Prince of Wales Hospital at 4 weeks after discharge, 6, 12, 18 and 24 months.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • third dose vaccination with CoronaVac vaccine

    Biological/Vaccine

    Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine

  • third dose vaccination with BionTech vaccine

    Biological/Vaccine

    Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine

  • Vaccination with Coronavac vaccine

    Biological/Vaccine

    Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart

  • Vaccination with BionTech Vaccine

    Biological/Vaccine

    Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart

Treatment groups

700 Participants
are divided into 5 treatment groups
Group A: COVID survivors0 interventions
Group B: Vaccination with CoronaVac vaccine1 intervention
Group C: Vaccination with BionTech vaccine1 intervention
Group D: third dose vaccination with CoronaVac vaccine1 intervention
Group E: third dose vaccination with BionTech vaccine1 intervention

Trial outcomes

Primary outcomes

1

spirometry

FEV1 and FVC

Time frame
3 years
2

Lung volume

Litres

Time frame
3 years
3

6 minute walk distance

meters

Time frame
3 years

Secondary outcomes

1

quality of life by SF36 questionnaire

scores in all domains

Time frame
3 years
2

serology and T cell response

titers

Time frame
3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chinese University of Hong Kong

Lead sponsor

The University of Hong Kong

Collaborator

Health and Medical Research Fund

Collaborator

Source ClinicalTrials.gov
Apply now